How large is the molluscum contagiosum (mc) treatment market, and what is its growth trajectory?
The molluscum contagiosum (MC) treatment market size has grown strongly in recent years. It will grow from $2.93 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rise in awareness about skin infections and their treatments, increase in pediatric cases, increase in healthcare spending, rise in the number of immunocompromised individuals, increase in funding from private and government organizations.
The molluscum contagiosum (MC) treatment market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing preference for non-invasive treatments, increasing prevalence of skin diseases, increasing demand for healthcare, rising prevalence of chronic diseases, increasing availability of advanced treatment options. Major trends in the forecast period include shift toward cosmetic treatment, development of topical delivery systems, shift towards at-home treatments, advancements in cryotherapy, focus on pediatric treatment options.
Get Your Free Sample of The Global Molluscum Contagiosum (MC) Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21225&type=smp
What are the key forces behind the molluscum contagiosum (mc) treatment market’s growth in recent years?
The rising demand for minimally invasive treatments is expected to propel the growth of the molluscum contagiosum treatment market going forward. Minimally invasive treatments refer to medical procedures performed with minimal damage to the body, usually involving small incisions or no incisions. The demand for minimally invasive treatments is attributed to their ability to reduce recovery time, minimize surgical risks, and enhance patient outcomes compared to traditional procedures. Molluscum contagiosum treatment uses minimally invasive methods such as cryotherapy and laser therapy for effective removal, faster recovery, and less scarring. Minimally invasive treatments typically require fewer visits and are well-suited for treating the often widespread lesions in molluscum contagiosum. For instance, in February 2024, according to the American Academy of Facial Plastic and Reconstructive Surgery, a US-based non-profit organization, in 2023, minimally invasive procedures accounted for 83% of all medical procedures accounting for 35 million procedures in 2023, while traditional surgical procedures made up the remaining 17%. Therefore, the rising demand for minimally invasive treatments is driving the growth of the molluscum contagiosum treatment market.
What are the major segments of the molluscum contagiosum (mc) treatment market?
The molluscum contagiosum (MC) treatment market covered in this report is segmented –
1) By Type: Molluscum Contagiosum Virus (MCV) -1, Molluscum Contagiosum Virus (MCV) -2, Molluscum Contagiosum Virus (MCV) -3, Molluscum Contagiosum Virus (MCV) -4
2) By Treatment Type: Topical Therapy, Immune-Modulators And Procedural Treatments
3) By Route Of Administration: Topical, Oral
4) By End User: Hospitals, Dermatology Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Molluscum Contagiosum Virus (MCV) -1: Topical Treatments, Cryotherapy, Curettage
2) By Molluscum Contagiosum Virus (MCV) -2: Topical Treatments, Cryotherapy, Curettage
3) By Molluscum Contagiosum Virus (MCV) -3: Topical Treatments, Cryotherapy, Curettage
4) By Molluscum Contagiosum Virus (MCV) -4: Topical Treatments, Cryotherapy, Curettage
Order your report now for swift delivery
Which companies dominate the molluscum contagiosum (mc) treatment market?
Major companies operating in the molluscum contagiosum (MC) treatment market are Verrica Pharmaceuticals, Novan Inc., Veloce BioPharma LLC, Gurina Foundation, Competition Deep Dive, Azafaros, Polaryx Therapeutics, Abbott Medtronic, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis, Ligand Pharmaceuticals Incorporated, Aclaris Therapeutics Inc., Verrica Pharmaceuticals Inc., Nielsen BioSciences Inc., MedCara Pharmaceuticals LLC, Gurina Foundation, Veloce BioPharma LLC, Labo ACM
What major trends will shape the molluscum contagiosum (mc) treatment market during the forecast period?
Major companies operating in the molluscum contagiosum (MC) treatment market are focusing on developing innovative products such as topical gel to enhance efficacy, improve patient compliance, and provide non-invasive treatment options. A topical gel is a semi-solid substance applied to the skin or mucous membranes for localized treatment or therapeutic effects. For instance, in April 2024, Ligand Pharmaceuticals Incorporated, a US-based biopharmaceutical company, launched Pelthos Therapeutics to commercialize Zelsuvmi (brazier) topical gel, 10.3%, the first Food and Drug Administration)-approved at-home treatment for molluscum contagiosum in adults and children over one-year-old. It is a nitric oxide-releasing gel designed to disrupt viral replication, leading to the clearance of lesions. Zelsuvmi offers a non-invasive, painless alternative to traditional in-office procedures such as cryotherapy or curettage, making it a practical and convenient option for patients aged one year and older.
What are the key regional dynamics of the molluscum contagiosum (mc) treatment market, and which region leads in market share?
North America was the largest region in the molluscum contagiosum (MC) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molluscum contagiosum (MC) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Molluscum Contagiosum (MC) Treatment Market Report 2025 Offer?
The molluscum contagiosum (mc) treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Molluscum contagiosum (MC) treatment refers to the medical interventions and methods used to manage and resolve molluscum contagiosum, a viral skin infection caused by a poxvirus. The goal of treatment is to remove the characteristic lesions, prevent further spread of the virus, and alleviate any associated discomfort, although the infection often resolves on its own in healthy individuals.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21225
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
